The Peptide NewsroomPeptide research, industry and supply-chain headlines

GELITA Says Three Studies Back Collagen Peptides for Endurance, But the Numbers Stay Behind a Paywall

Topic card: collagen muscle

An industry article published by Nutraceutical Business Review says the collagen manufacturer GELITA investigated whether continuous preparatory supplementation with specific Bioactive Collagen Peptides could improve endurance performance, and reports that three studies using its PeptENDURE ingredient produced significant results.

Bioactive Collagen Peptides, abbreviated to BCPs in the trade press, are short collagen-derived protein fragments sold to supplement brands as named ingredients. PeptENDURE is GELITA's own formulation, developed, according to the article, specifically for endurance athletes.

Why lactate is the measure

The piece builds its case on blood lactate, which it describes as a reliable indicator of how the body is responding to endurance exercise. Lactate is a by-product of fast, oxygen-independent energy production from carbohydrates, the pathway the body draws on during intense physical effort.

When lactate levels rise sharply, the article says, muscle metabolism becomes acidic and fatigue follows. That makes lactate a sensible outcome to measure in an endurance study, and it is a more specific endpoint than the vague performance language that usually accompanies sports ingredients.

The established part, and the new part

Carbohydrate and electrolyte drinks are already well established for delivering fast energy when fatigue sets in, and the article says so plainly. The novel claim is not about energy during a session but about supplementing continuously beforehand, which is a different question and a harder one to demonstrate.

Training improves performance, the article notes, but nutrition also plays a role in sustaining speed and stamina. That framing is uncontroversial. Whether a specific collagen peptide moves a lactate curve is not.

What is not public here

The article is a paid extract, and the portion available to non-subscribers stops before any result appears. No sample size, no trial design, no effect size, no lactate figure, and no indication of whether the three studies were published or peer reviewed.

This is also manufacturer-originated research reported in a trade outlet, which is not disqualifying but is worth naming. "Significant results" from a company describing studies of its own ingredient is a claim about the studies, not a finding anyone outside the paywall can check.

Bottom line

The endpoint is well chosen and the question is a real one: endurance supplementation is a crowded category built on thin evidence, and lactate data would be a genuine contribution. Until the three studies are visible, there is nothing here to weigh.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: collagen, muscle, recovery

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

US Draft Policy Would Ease Access to Six Peptides, But None Are FDA-Approved

A draft US policy would allow licensed compounding pharmacies to prepare BPC-157, TB-500, MOTS-c, Epitalon, KPV and Semax on prescription, none of which the FDA has approved. An Indian endocrinologist warns the move could be misrepresented abroad as evidence that the compounds have been medically validated.

KFF Health News Flags Four Misleading Peptide Claims as FDA Weighs Looser Rules

A KFF Health News analysis republished by The Good Men Project flags four misleading phrases used to market experimental peptides, as a White House docket proposes letting pharmacies sell unapproved ones. FDA scientists advised against the change; an advisory panel stacked with industry-linked appointees voted for it.

HHS Eases Enforcement on Compounded Peptides, But Approval Is Not What Changed

HHS published an interim policy on October 30 relaxing enforcement on compounding six peptides, following an FDA advisory committee vote that agency staff opposed. The policy covers patient-specific compounding under Section 503A, not FDA approval.